



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
90/007,542 ✓ 47554	05/13/2005	6331415	22338-10230	7585

90/007859
7590 02/16/2007
SIDLEY AUSTIN LLP
ATTN: DC PATENT DOCKETING
1501 K STREET, NW
WASHINGTON, DC 20005

EXAMINER

ART UNIT PAPER NUMBER

DATE MAILED: 02/16/2007

Please find below and/or attached an Office communication concerning this application or proceeding.



DO NOT USE IN PALM PRINTER

(THIRD PARTY REQUESTER'S CORRESPONDENCE ADDRESS)

LISA V. MUELLER

WOOD PHILLIPS KATZ CLARK & MORTIMER

3800 WEST MADISON STREET, SUITE 3800

CHICAGO, IL 60661

EX PARTE REEXAMINATION COMMUNICATION TRANSMITTAL FORM

REEXAMINATION CONTROL NO. 90/007,542. (901007, 859)

PATENT NO. 6331415.

ART UNIT 3991.

Enclosed is a copy of the latest communication from the United States Patent and Trademark Office in the above identified *ex parte* reexamination proceeding (37 CFR 1.550(f)).

Where this copy is supplied after the reply by requester, 37 CFR 1.535, or the time for filing a reply has passed, no submission on behalf of the *ex parte* reexamination requester will be acknowledged or considered (37 CFR 1.550(g)).

Office Action in Ex Parte Reexamination	Control No. 90/007,542 (90/007,859)	Patent Under Reexamination 6331415	
	Examiner Bennett Celsa	Art Unit 3991	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

- a Responsive to the communication(s) filed on 30 October 2006. b This action is made FINAL.
c A statement under 37 CFR 1.530 has not been received from the patent owner.

A shortened statutory period for response to this action is set to expire 2 month(s) from the mailing date of this letter. Failure to respond within the period for response will result in termination of the proceeding and issuance of an *ex parte* reexamination certificate in accordance with this action. 37 CFR 1.550(d). **EXTENSIONS OF TIME ARE GOVERNED BY 37 CFR 1.550(c)**. If the period for response specified above is less than thirty (30) days, a response within the statutory minimum of thirty (30) days will be considered timely.

Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:

1. Notice of References Cited by Examiner, PTO-892. 3. Interview Summary, PTO-474.
2. Information Disclosure Statement, PTO/SB/08. 4. _____

Part II SUMMARY OF ACTION :

- 1a. Claims 1-36 are subject to reexamination.
1b. Claims _____ are not subject to reexamination.
2. Claims _____ have been canceled in the present reexamination proceeding.
3. Claims _____ are patentable and/or confirmed.
4. Claims 1-36 are rejected.
5. Claims _____ are objected to.
6. The drawings, filed on _____ are acceptable.
7. The proposed drawing correction, filed on _____ has been (7a) approved (7b) disapproved.
8. Acknowledgment is made of the priority claim under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some* c) None of the certified copies have

- 1 been received.
2 not been received.
3 been filed in Application No. _____
4 been filed in reexamination Control No. _____
5 been received by the International Bureau in PCT application No. _____

* See the attached detailed Office action for a list of the certified copies not received.

9. Since the proceeding appears to be in condition for issuance of an *ex parte* reexamination certificate except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte* Quayle, 1935 C.D. 11, 453 O.G. 213.
10. Other: _____

Art Unit: 3991

Reexamination: Final Office Action

Reexamination of US Patent No. 6,331,415 (Cabilly 2 patent).

Status of the Claims

Claims 1-36 are pending and under reexamination. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Procedural Posture:

Merger of 3rd Partly Requests 90/007,542 and 90/007,859

i. 90/007542 ('7542 Proceeding):		ii. 90/007859 ('7859 Proceeding)	
Reexamination request filed:	5/13/05		12/23/05
Reexamination ordered:	7/7/05		1/23/06
Patent Owner Statement:	none		none
First Office Action mailed:	9/13/05		N/A
Patent Owner Response dated	1/25/05		N/A
'7542 AND '7859 merged:		6/6/06	

Following the merger of the 90/007,542 and 90/007,859 proceedings, the First Office Action dated September 13, 2005 in the '7542 proceeding was withdrawn in light of the Non-Final Office Action dated August 16, 2006.

Patentee's November 25, 2005 response (with Declarations) and the November 30, 2006 response (with Declarations) to the September 13, 2005 and subsequent August 16 2006 office actions, respectively in the 90/007,542 proceeding are considered in this office action.

Additionally, the submitted December 14, 2006 and January 16, 2007 information-disclosure statement have been considered in this office action.

Information Disclosure Statement (IDS)

Examiner-initialed copies of the December 14, 2006 IDS (four pages) and the

Art Unit: 3991

January 16, 2007 IDS (thirty pages) submitted under Rule 1.97(c), (requiring 1.17(p) fees), accompany this office action. The newly submitted Moore 5,840,545 Patent reference presented in the Dec. 14th IDS necessitated the making of the new grounds of rejection found in this office action.

There is a substantial new question of patentability raised by the Moore 5,840,545 patent. The Moore patent was cited by the Examiner in an anticipation rejection in a related co-pending application (U.S.S.N. 08/422,187) but is now being viewed in a new light since the claims addressed in 08/422,187 were drawn to different subject matter (e.g. process for producing altered antibody heavy or light chain or fragments thereof).

Priority

The 6,331,425 (Cabilly 2) patent undergoing reexamination issued on December 18, 2001 from application 07/205,419 (filed 6/10/88) which was a continuation of 06/483,457 (filed 4/8/83) now 4,816,567 (Cabilly 1) patent.

Cumulative Prior Art :

The 1982 Valle and Deacon references are cumulative in their teaching of microinjection of mRNA encoding light and heavy immunoglobulin chains into *Xenopus* oocyte cells to produce secreted active antibody. Accordingly, only the Deacon reference was utilized in the obviousness double patenting rejection(s) recited below.

Additionally, the Oi and Ochi references are cumulative in their teaching of restoring hybridoma cell antibody expression by vector transformation with a light chain

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.